Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phytosun Decongestant is a hypertonic seawater-based nasal spray enriched with essential oils, including Eucalyptus globulus, Melaleuca quinquenervia (Niaouli), and Mentha arvensis (Wild Mint). Registered as a Class I medical device in the European Union, it is indicated for the symptomatic relief of nasal congestion associated with the common cold and rhinopharyngitis. The product works primarily through an osmotic effect provided by the hypertonic saline solution, which draws excess fluid from the nasal mucosa to reduce swelling and edema. This mechanical action is complemented by the aromatic properties of the essential oils, which provide a refreshing sensation and may offer additional decongestant benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phytosun Decongestant.